Global cell line development market to witness robust growth through 2026

May 12, 2020

According the research report titled ‘Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research) Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026’, available with Market Study Report LLC, global cell line development market is expected to generate prominent returns by the  year 2026.

Increased pervasiveness of chronic conditions along with rapid technological advancements in the healthcare field are major factors driving the growth of cell line development industry. The market is expected to further expand owing to amplification of biotechnology sector.

As per the product type, accessories & consumables segment held a substantial market share in 2019 and is presumed to expand with a CAGR of 15% through 2026. Surging investments towards establishment of advanced laboratories have impelled the demand for accessories & consumables including culture vessels, globes, bottles, syringes etc.

In terms of source, mammalian segment was worth USD 3 billion in 2019 and is projected to witness lucrative growth in the subsequent years, primarily due to advancements in technology pertaining to cell line engineering.

As per the report, primary cell line segment held 19% market share in 2019 and is expected to register remunerative growth during the study period. Increasing utilization of primary cell lines in medical research along with development of 3D cell culture technologies are fueling the growth of the segment.

Cell line development market share from the drug discovery application is projected to cross USD 1 billion by the year 2026. High occurrence of cancer and autoimmune diseases among the global population along with growing demand for treatment drugs are favoring the adoption of cell line development for drug discovery activities. For instance, WuXi and Vir Biotechnology recently announced collaboration to develop an antibody based potential treatment for the recent pandemic, COVID-19.

Request sample copy of this Report:

The prominent companies in cell line development industry are Epistem Holdings Plc., Promocell, Abzena PLC, Bioceros, Catalent Inc., Apath LLC and Cobra Biologics among others. The market is slated to record a considerable growth rate through 2026, owing to technological advancements and increasing business-centric activities adopted by market majors. For instance, FUJIFILM Diosynth Biotechnologies recently unveiled its plan to expand its operations by establishing “Flexible Biomanufacturing Facility” in the state of Texas.